AMAG Pharmaceuticals, Inc. (AMAG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile by GlobalData

VIEWS: 0 PAGES: 21

AMAG Pharmaceuticals, Inc. (AMAG), formerly known as Advanced Magnetics, Inc., is biopharmaceutical company with focus on the development, manufacture and marketing of therapeutic iron compounds to treat iron deficiency anemia (IDA). The company's proprietary technology and expertise to synthesize, sterilize and stabilize these iron oxide nanoparticles such that they can be used in pharmaceutical products like iron replacement therapeutics and magnetic resonance imaging (MRI) contrast agents to detect cancer and cardiovascular diseases. The product portfolio of AMAG include Feraheme (ferumoxytol) and GastroMARK (ferumoxsil, oral suspension). Its product GastroMARK is an oral gastrointestinal imaging agent for the delineation of the bowel. The company markets its product Feraheme through its own sales force and through license grant. The company operates in the US, Europe, Japan and Asia. AMAG is headquartered in Massachusetts, the US.

More Info
									        AMAG Pharmaceuticals, Inc. (AMAG) - Pharmaceuticals & Healthcare - Deals
                                 and Alliances Profile
       Reference Code: GDPH3552D                                                                                                          Publication Date: MAR 2013

      Company Overview                                                                                        Key Facts
      AMAG Pharmaceuticals, Inc. (AMAG), formerly known as Advanced Magnetics, Inc.,
                                                                                                              AMAG Pharmaceuticals, Inc., Pharmaceuticals &
      is biopharmaceutical company with focus on the development, manufacture and
                                                                                                              Healthcare, Key Facts, 2011
      marketing of therapeutic iron compounds to treat iron deficiency anemia (IDA). The
      company's proprietary technology and expertise to synthesize, sterilize and stabilize                    Web Address                     www.amagpharma.com
      these iron oxide nanoparticles such that they can be used in pharmaceutical
                                                                                                               Revenue (US$ million)                                 61.25
      products like iron replacement therapeutics and magnetic resonance imaging (MRI)
      contrast agents to detect cancer and cardiovascular diseases. The product portfolio                      Number of Employees                                    174
      of AMAG include Feraheme (ferumoxytol) and GastroMARK (ferumoxsil, oral                                  GlobalData
      suspension).

      Financial Deals Landscape
        AMAG Pharmaceuticals, Inc., Pharmaceuticals & Healthcare,                         AMAG Pharmaceuticals, Inc., Pharmaceuticals &
        Deals by Type, 2007 to YTD 2013                                                   Healthcare, Deals By Year, 2007 to YTD 2013


                                                                                                                                      2
                                                                                                          2

                                                                                           No. of Deals
                                                                                                                 1     1
                                                                                                          1


                                                                                                                              0                0       0         0
                                                                                                          0
                                                                                                               2007   2008   2009   2010    2011      2012   YTD
                                                                                                                                                             2013


                                                                                          Note: Deals include all announced pharmaceuticals & healthcare deals
         Note: Deals include all announced pharmaceuticals & healthcare deals from
                                                                                          from 2006 onwards, GlobalData
         2006 onwards, GlobalData


         AMAG Pharmaceuticals, Inc., Pharmaceuticals &                                    AMAG Pharmaceuticals, Inc., Pharmaceuticals &
         Healthcare, Deals By Region, 2007 to YTD 2013                                    Healthcare, Deals By Therapy Area, 2007 to YTD 2013


                         3                                                                                             2
          No. of Deals




                               3        2                                                                 2
                                                                                           No. of Deals




                         2
                                                  1
                         1                                                                                                            1                1
                                                           0         0                                    1
                         0
                             North    Asia-     Europe   Middle   South
                             Americ   Pacific             East     and
                               a                          and     Central                                 0
                                                         Africa   Americ                                           Hematologi     Cardiovasc       Gastrointes
                                                                    a                                             cal D isord …      ular             tinal


         Note: Deals include all announced pharmaceuticals & healthcare deals             Note: Deals include all announced pharmaceuticals & healthcare deals
         from 2006 onwards, GlobalData                                                    from 2006 onwards, GlobalData




AMAG Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare -                                                                                    Reference Code: GDPH3552D
Deals and Alliances Profile
Source : www.globalcompanyintelligence.com                                                                                                                                   Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       AMAG Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 .................................................... 4
       AMAG Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2007 to YTD 2013 .................................................... 5
       AMAG Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2007 to YTD 2013 ................................................ 6
       AMAG Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2007 to YTD 2013 ...................................... 7
       AMAG Pharmaceuticals, Inc., Medical Devices Deals, 2007 to YTD 2013......................................................................................... 8
       AMAG Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2007 to YTD 2013 ................................................. 9
       AMAG Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details .................................................................................... 10
          Licensing Agreements .................................................................................................................................................................. 10
             AMAG Pharma Enters Into Licensing Agreement With Takeda Pharma ................................................................................... 10
             3SBio Enters Into Licensing Agreement With AMAG Pharma For Ferumoxytol........................................................................ 12
          Equity Offering .............................................................................................................................................................................. 14
             AMAG Pharma Completes Public Offering Of $174 Million ....................................................................................................... 14
             AMAG Pharma Completes Public Offering Of $162.85 Million .................................................................................................. 16
       AMAG Pharmaceuticals, Inc. - Key Competitors .............................................................................................................................. 18
       Key Employees ................................................................................................................................................................................ 19
       Locations And Subsidiaries .............................................................................................................................................................. 20
          Head Office ................................................................................................................................................................................... 20
          Other Locations & Subsidiaries ...............................................................................
								
To top